Mechanisms of action of therapeutic amyloidogenic hexapeptides in amelioration of inflammatory brain disease

15Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Amyloid fibrils composed of peptides as short as six amino acids are effective therapeutics for experimental autoimmune encephalomyelitis (EAE). Immunosuppression arises from at least two pathways: (1) expression of type 1 IFN by pDCs, which were induced by neutrophil extracellular traps arising from the endocytosis of the fibrils; and (2) the reduced expression of IFN-γ, TNF, and IL-6. The two independent pathways stimulated by the fibrils can act in concert to be immunosuppressive in Th1 indications, or in opposition, resulting in inflammation when Th17 T lymphocytes are predominant. The generation of type 1 IFN can be minimized by using polar, nonionizable, amyloidogenic peptides, which are effective in both Th1 and Th17 polarized EAE. © 2014 Kurnellas et al.

Cite

CITATION STYLE

APA

Kurnellas, M. P., Schartner, J. M., Fathman, C. G., Jagger, A., Steinman, L., & Rothbard, J. B. (2014). Mechanisms of action of therapeutic amyloidogenic hexapeptides in amelioration of inflammatory brain disease. Journal of Experimental Medicine, 211(9), 1847–1856. https://doi.org/10.1084/jem.20140107

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free